Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) EBIT: 2020-2024

Historic EBIT for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to -$145.6 million.

  • Tango Therapeutics' EBIT rose 142.80% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 21.02%. This contributed to the annual value of -$145.6 million for FY2024, which is 27.52% down from last year.
  • Latest data reveals that Tango Therapeutics reported EBIT of -$145.6 million as of FY2024, which was down 27.52% from -$114.2 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' EBIT ranged from a high of -$52.2 million in FY2020 and a low of -$145.6 million during FY2024.
  • For the 3-year period, Tango Therapeutics' EBIT averaged around -$123.6 million, with its median value being -$114.2 million (2023).
  • Data for Tango Therapeutics' EBIT shows a maximum YoY crashed of 90.88% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Tango Therapeutics' EBIT stood at -$52.2 million in 2020, then decreased by 11.48% to -$58.2 million in 2021, then crashed by 90.88% to -$111.1 million in 2022, then dropped by 2.79% to -$114.2 million in 2023, then dropped by 27.52% to -$145.6 million in 2024.